For the quarter ended June 2026, Collegium Pharmaceutical (COLL) reported revenue of $199.88 million, up 6.3% over the same period last year. EPS came in at $1.92, compared to $1.68 in the year-ago quarter.

The reported revenue represents a surprise of +1.2% over the Zacks Consensus Estimate of $197.5 million. With the consensus EPS estimate being $1.68, the EPS surprise was +14.29%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total product revenues- Belbuca: $57.67 million versus $56.31 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change.
  • Total product revenues- Xtampza ER: $45.01 million versus $49.41 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -14.5% change.
  • Total product revenues- Jornay PM: $46.06 million versus $45.57 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +41.2% change.
  • Total product revenues- Nucynta (Nucynta IR+Nucynta ER): $30.08 million compared to the $42.31 million average estimate based on two analysts. The reported number represents a change of -35.2% year over year.
  • Total product revenues- Symproic: $3.02 million versus the two-analyst average estimate of $3.92 million. The reported number represents a year-over-year change of -18.9%.

View all Key Company Metrics for Collegium Pharmaceutical here>>>

Shares of Collegium Pharmaceutical have returned -0.3% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Collegium Pharmaceutical, Inc. (COLL): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research